PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16230218-0	2005	Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness.	Cefepime	118-126	EsbL	Escherichia coli	59-63	
16230218-1	2005	OBJECTIVE: To determine the affect of ESBL production among Klebsiella species and Escherichia coli on cefepime effectiveness.	Cefepime	103-111	EsbL	Escherichia coli	38-42	
16230218-2	2005	METHODS: This was a retrospective, case-controlled study comparing the clinical and microbiologic responses of patients receiving cefepime for ESBL producing Klebsiella species or E. coli from a non-urine source with matched controls receiving cefepime for non-ESBL strains.	Cefepime	130-138	EsbL	Escherichia coli	143-147	
16230218-2	2005	METHODS: This was a retrospective, case-controlled study comparing the clinical and microbiologic responses of patients receiving cefepime for ESBL producing Klebsiella species or E. coli from a non-urine source with matched controls receiving cefepime for non-ESBL strains.	Cefepime	130-138	EsbL	Escherichia coli	261-265	
16230218-9	2005	CONCLUSION: These data indicate that ESBL production among non-urinary Klebsiella species and E. coli negatively affected cefepime effectiveness.	Cefepime	122-130	EsbL	Escherichia coli	37-41